Literature DB >> 631143

Effect of prolonged ingestion of gamma-linolenate by MS patients.

E J Field, G Joyce.   

Abstract

The absolute electrophoretic mobility of erythrocytes from MS patients is reduced in the presence of 0.08 mg/ml of linoleic or arachidonic acid, whilst that of normal or other neurological disease patients is increased in the presence of these acids. When an MS patient ingests gamma-linolenate (in capsule form equivalent to 413.4 mg of gamma-linolenic acid and 2.664 g of linoleic acid per day) the reaction of MS erythrocytes begins to change. After 3 or 4 months the reaction becomes normal with arachidonic acid (i.e. mobility is speeded up) and 2 months or so later this occurs also with linoleic acid. Very prolonged administration of gamma-linolenate leads to a markedly increased sensitivity to the effect of prostaglandins (PGE2) on RBC mobility. The observations are interpreted to mean the induction of a biochemical-biophysical change in the membranes, and the significance of this in the aetiology and treatment of multiple sclerosis is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 631143     DOI: 10.1159/000114926

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  7 in total

1.  Multiple sclerosis: what can and cannot be done.

Authors:  E J Field; G Joyce
Journal:  Br Med J       Date:  1979-12-15

2.  Polyunsaturated fatty acids and colchicine in multiple sclerosis.

Authors: 
Journal:  Br Med J       Date:  1979-02-10

3.  Multiple sclerosis: what can and cannot be done.

Authors:  E J Field; G Joyce
Journal:  Br Med J       Date:  1980-05-17

4.  Simplified E-UFA test for multiple sclerosis (MS): some sources of "false" results.

Authors:  E J Field; G Joyce
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

5.  Linoleic acid therapy in severe experimental allergic encephalomyelitis in the guinea-pig: suppression by continuous treatment.

Authors:  D Hughes; A B Keith; J Mertin; E A Caspary
Journal:  Clin Exp Immunol       Date:  1980-06       Impact factor: 4.330

6.  Multiple sclerosis: treatment and prophylaxis.

Authors:  E J Field
Journal:  J R Soc Med       Date:  1979-07       Impact factor: 18.000

Review 7.  Multiple sclerosis.

Authors:  Alan Gaby
Journal:  Glob Adv Health Med       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.